ERBB2 and non-small cell lung carcinoma: Conversely, the combination of volrustomig and rilvegostomig and T-DXd with or without chemotherapy will be specifically evaluated in patients with NSCLC and HER2 overexpression in the phase Ib DESTINY-Lung03 (NCT04686305) trial.